P669: FIXED‐DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3‐YEAR FOLLOW‐UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT.

Autor:	Moreno, C., Wierda, W. G., Barr, P. M., Siddiqi, T., Allan, J. N., Kipps, T. J., Trentin, L., Jacobs, R., Jackson, S., Tedeschi, A., Opat, S., Bannerji, R., Kuss, B. J., Croner, L. J., Szafer‐Glusman, E., Zhou, C., Szoke, A., Dean, J. P., Ghia, P., Tam, C. S.
Zdroj:	HemaSphere; 2022 Supplement 3, Vol. 6, p567-568, 2p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text